Feature|Articles|August 28, 2026

Preventing Batch Loss: The Growing Role of Preventive and Predictive Maintenance

Author(s)Israel Ortiz

With biopharma batch failures averaging every 40 weeks, predictive maintenance and connected monitoring are becoming critical quality levers.

Pharmaceutical manufacturers operate under some of the strictest quality requirements in any industry. Even small deviations in a facility’s environmental conditions can compromise product stability and risk batch losses that can cost manufacturers millions of dollars in lost product, investigations, and production delays. Despite improvements in manufacturing technology, batch failures still occur due to contamination, operator error, and equipment failure. On average, biopharmaceutical manufacturers experience a failure every 40 weeks.

Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.